B. Dutzar

Targeting of Lipid-Protamine-DNA (LPD) Lipopolyplexes Using RGD Motifs

P. Harvie, S. Cudmore, T. Galbraith, 2003, Journal of liposome research.

ALD1613, a Novel Long-Acting Monoclonal Antibody to Control ACTH-Driven Pharmacology

J. Mulligan, J. Latham, M. Scalley‐Kim, 2016, Endocrinology.

Pharmacologic Characterization of ALD403, a Potent Neutralizing Humanized Monoclonal Antibody Against the Calcitonin Gene-Related Peptide

J. Latham, M. Scalley‐Kim, B. Baker, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide

J. Mulligan, R. Cady, S. Pederson, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Calculating expected lung deposition of aerosolized administration of AAV vector in human clinical studies

A. Coates, K. Munson, P. Anklesaria, 2007, The journal of gene medicine.

In vivo efficacy of folate-targeted lipid–protamine–DNA (LPD-PEG-Folate) complexes in an immunocompetent syngeneic model for breast adenocarcinoma

E. Bruckheimer, P. Harvie, P. Anklesaria, 2004, Cancer Gene Therapy.